Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1859 1
1892 1
1905 1
1917 2
1927 1
1935 1
1936 1
1937 1
1938 3
1939 2
1940 2
1943 1
1944 1
1945 8
1946 8
1947 10
1948 5
1949 8
1950 8
1951 11
1952 9
1953 8
1954 6
1955 9
1956 5
1957 14
1958 14
1959 16
1960 25
1961 19
1962 14
1963 4
1964 17
1965 27
1966 10
1967 26
1968 30
1969 31
1970 16
1971 10
1972 27
1973 35
1974 27
1975 31
1976 28
1977 26
1978 35
1979 36
1980 33
1981 40
1982 49
1983 31
1984 41
1985 50
1986 48
1987 44
1988 41
1989 52
1990 76
1991 98
1992 85
1993 62
1994 86
1995 93
1996 93
1997 106
1998 109
1999 84
2000 105
2001 111
2002 122
2003 132
2004 130
2005 157
2006 148
2007 161
2008 185
2009 232
2010 218
2011 276
2012 314
2013 295
2014 337
2015 326
2016 315
2017 339
2018 345
2019 345
2020 412
2021 462
2022 429
2023 421
2024 379

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,830 results

Results by year

Filters applied: . Clear all
Page 1
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA III, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L. Armstrong DK, et al. Among authors: martin l. J Natl Compr Canc Netw. 2022 Sep;20(9):972-980. doi: 10.6004/jnccn.2022.0047. J Natl Compr Canc Netw. 2022. PMID: 36075393
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. Among authors: martin lp. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
Noncardiogenic pulmonary edema in small animals.
Unger K, Martin LG. Unger K, et al. Among authors: martin lg. J Vet Emerg Crit Care (San Antonio). 2023 Mar;33(2):156-172. doi: 10.1111/vec.13278. Epub 2023 Feb 23. J Vet Emerg Crit Care (San Antonio). 2023. PMID: 36815753 Review.
Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial.
Mendoza M, Bonacina E, Garcia-Manau P, López M, Caamiña S, Vives À, Lopez-Quesada E, Ricart M, Maroto A, de Mingo L, Pintado E, Ferrer-Costa R, Martin L, Rodríguez-Zurita A, Garcia E, Pallarols M, Vidal-Sagnier L, Teixidor M, Orizales-Lago C, Pérez-Gomez A, Ocaña V, Puerto L, Millán P, Alsius M, Diaz S, Maiz N, Carreras E, Suy A. Mendoza M, et al. Among authors: martin l. JAMA. 2023 Feb 21;329(7):542-550. doi: 10.1001/jama.2023.0691. JAMA. 2023. PMID: 36809321 Free PMC article. Clinical Trial.
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
You B, Purdy C, Copeland LJ, Swisher EM, Bookman MA, Fleming G, Coleman R, Randall LM, Tewari KS, Monk BJ, Mannel RS, Walker JL, Cappuccini F, Cohn D, Muzaffar M, Mutch D, Wahner-Hendrickson A, Martin L, Colomban O, Burger RA. You B, et al. Among authors: martin l. J Clin Oncol. 2022 Dec 1;40(34):3965-3974. doi: 10.1200/JCO.22.01207. Epub 2022 Oct 17. J Clin Oncol. 2022. PMID: 36252167 Free PMC article. Clinical Trial.
Elucidation of the pathway for biosynthesis of saponin adjuvants from the soapbark tree.
Reed J, Orme A, El-Demerdash A, Owen C, Martin LBB, Misra RC, Kikuchi S, Rejzek M, Martin AC, Harkess A, Leebens-Mack J, Louveau T, Stephenson MJ, Osbourn A. Reed J, et al. Among authors: martin lbb. Science. 2023 Mar 24;379(6638):1252-1264. doi: 10.1126/science.adf3727. Epub 2023 Mar 23. Science. 2023. PMID: 36952412 Free article.
Powerful, scalable and resource-efficient meta-analysis of rare variant associations in large whole genome sequencing studies.
Li X, Quick C, Zhou H, Gaynor SM, Liu Y, Chen H, Selvaraj MS, Sun R, Dey R, Arnett DK, Bielak LF, Bis JC, Blangero J, Boerwinkle E, Bowden DW, Brody JA, Cade BE, Correa A, Cupples LA, Curran JE, de Vries PS, Duggirala R, Freedman BI, Göring HHH, Guo X, Haessler J, Kalyani RR, Kooperberg C, Kral BG, Lange LA, Manichaikul A, Martin LW, McGarvey ST, Mitchell BD, Montasser ME, Morrison AC, Naseri T, O'Connell JR, Palmer ND, Peyser PA, Psaty BM, Raffield LM, Redline S, Reiner AP, Reupena MS, Rice KM, Rich SS, Sitlani CM, Smith JA, Taylor KD, Vasan RS, Willer CJ, Wilson JG, Yanek LR, Zhao W; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium, TOPMed Lipids Working Group; Rotter JI, Natarajan P, Peloso GM, Li Z, Lin X. Li X, et al. Among authors: martin lw. Nat Genet. 2023 Jan;55(1):154-164. doi: 10.1038/s41588-022-01225-6. Epub 2022 Dec 23. Nat Genet. 2023. PMID: 36564505 Free PMC article.
Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
André T, Falcone A, Shparyk Y, Moiseenko F, Polo-Marques E, Csöszi T, Campos-Bragagnoli A, Liposits G, Chmielowska E, Aubel P, Martín L, Fougeray R, Amellal N, Saunders MP. André T, et al. Among authors: martin l. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):133-144. doi: 10.1016/S2468-1253(22)00334-X. Epub 2022 Dec 2. Lancet Gastroenterol Hepatol. 2023. PMID: 36470291 Clinical Trial.
Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer.
Wethington SL, Shah PD, Martin L, Tanyi JL, Latif N, Morgan M, Torigian DA, Rodriguez D, Smith SA, Dean E, Domchek SM, Drapkin R, Shih IM, Brown EJ, Hwang WT, Armstrong DK, Gaillard S, Giuntoli R, Simpkins F. Wethington SL, et al. Among authors: martin l. Clin Cancer Res. 2023 Aug 1;29(15):2800-2807. doi: 10.1158/1078-0432.CCR-22-2444. Clin Cancer Res. 2023. PMID: 37097611
7,830 results